Home / Ingredients / Echinacea
Evidence reviewed: 2026-10-02
Possible small effect on cold incidence for some preparations; evidence for shortening or treating colds remains uncertain and product-specific.
The 2014 Cochrane review found that echinacea products had not been shown to provide clear treatment benefit for colds, though a weak preventive effect from some preparations remained possible. Species, plant parts, and extraction methods vary widely, limiting generalization across products.
Clinical trials use different Echinacea species and preparations. Without species, plant part, extract, and dose information, direct comparison to the research is weak.
Short-term use is likely safe for many adults, but gastrointestinal effects and allergic reactions can occur. Drug interactions are possible, and evidence in children, pregnancy, and breastfeeding is limited.
V-ITALBOOST lists echinacea but does not publish species, plant part, extract standardization, or dose. Finished-product cold or immune claims therefore remain unverified.
Echinacea for preventing and treating the common cold (Cochrane systematic review; PMID 24554461)
Population/scope: 24 double-blind trials; 4,631 participants
Evidence scope: Prevention and treatment of the common cold
Finding: No clear treatment benefit was established; a weak preventive effect from some preparations remained possible.
Limitations: Strong clinical heterogeneity across species, plant parts, extracts, and trial methods prevented broad pooling and product-level generalization.
Directness: Relevant human evidence ยท verified 2026-10-02
Important: Ingredient-level evidence is not proof that a finished product has the same effect. Dose, form, population, duration, and formulation must match.
For informational purposes only; not individualized medical advice.